This content is from: Premium
Perceptive’s China Rx
The life sciences giant is one of at least seven hedge funds that have invested in LianBio, scheduled to go public this week. Here’s why this IPO is different.
Perceptive Advisors, a hedge fund firm well known for its public and private investments in life sciences and biopharma companies, is gearing up for the IPO of a company it actually founded.LianBio, a Chinese company focused on developing in-licensed therapies for the Chinese and other Asian markets, plans to sell
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.